A. Innes

发表

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.

S. Schreiber, P. Rutgeerts, M. Kamm, 2005, Gastroenterology.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

N. Goel, V. Strand, J. Vencovský, 2008, Annals of the rheumatic diseases.

CDP571, a Humanized Anti-Tumor Necrosis Factor-&agr; Monoclonal Antibody in Pediatric Crohn’s Disease

R. Baldassano, B. Kirschner, A. Innes, 2004, Inflammatory bowel diseases.

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

N. Goel, V. Strand, J. Vencovský, 2008, Annals of the rheumatic diseases.

Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis

T. Rudge, T. Guina, A. Innes, 2013, Clinical and Vaccine Immunology.

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

G. Radford-Smith, R. Enns, W. Sandborn, 2004, Gut.

CDP 571 , a humanised monoclonal antibody to tumour necrosis factor a , for moderate to severe Crohn ’ s disease : a randomised , double blind , placebo controlled trial

G. Radford-Smith, R. Enns, B. Feagan, 2004 .

BIOTHRAX ® (ANTHRAX VACCINE ADSORBED) FOR POST-

T. Rudge, T. Guina, A. Innes, 2013 .

Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study

A. Innes, J. Wright, T. Winter, 2004, Alimentary pharmacology & therapeutics.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

C. Hermans, D. Perry, M. Ozelo, 2015, British journal of haematology.

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A‐LONG study subjects with severe haemophilia A

D. Perry, D. Quon, J. Mahlangu, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Subject-Reported Changes in Physical Activity During The B-LONG Study of Recombinant Factor IX FC Fusion Protein (RFIXFC) For Severe Haemophilia B

M. Ozelo, M. Ragni, J. Windyga, 2015 .

The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial

James R. Robinson, M. Orr, P. Brownson, 2019, The Lancet.

CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial

G. Radford-Smith, W. Sandborn, B. Feagan, 2006, Alimentary pharmacology & therapeutics.

Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study

Theresa M. Marteau, Nicholas P. J. Day, Linda Sharp, 2009, BMJ : British Medical Journal.